• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    $ICU
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER HERE

    Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams.

    Schedule 1x1 meetings here

    "We are delighted to highlight today's innovators from the Life Science sector," said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. "Our Virtual Investor Conferences continue to provide an efficient platform and unique opportunity for these companies to engage to a broader investor base and communicate their strategies."

    March 11th

    Eastern

    Time (ET)
    PresentationTicker(s)
    12:00 PMSeaStar Medical Holding Corporation(NASDAQ:ICU)
    12:30 PMNasus Pharma Ltd.(NYSE:NSRX)
    1:00 PMTonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP)
    1:30 PMJupiter Neurosciences, Inc.(NASDAQ:JUNS)



    March 12th

    Eastern

    Time (ET)
    PresentationTicker(s)
    09:30 AMBora Pharmaceuticals Co., Ltd.(OTCQX:BORAY, TWSE: 6472))
    10:00 AMProstatype Genomics AB(OTCQB:PGABF, NASDAQ Stockholm: PROGEN)) 
    10:30 AMMetaVia Inc.(NASDAQ:MTVA)
    11:00 AMPhio Pharmaceuticals Corp.(NASDAQ:PHIO)
    11:30 AMAvicanna Inc.(OTCQX:AVCNF, TSX:AVCN)
    12:00 PMEMVision Medical Devices Ltd.(OTC:EMVDF, ASX: EMV))
    1:00 PMAethlon Medical, Inc.(NASDAQ:AEMD)
    1:30 PMDyadic International, Inc.(NASDAQ:DYAI)
    2:00 PMJaguar Health, Inc.(NASDAQ:JAGX)
    2:30 PMBeyond Air, Inc.(NASDAQ:XAIR)
    3:00 PMCadrenal Therapeutics, Inc.(NASDAQ:CVKD)
    3:30 PMAmplia Therapeutics Ltd.(OTCQB:INNMF, ASX: ATX))



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $CVKD
    $DYAI
    $ICU

    CompanyDatePrice TargetRatingAnalyst
    Dyadic International Inc.
    $DYAI
    10/23/2025$3.00Buy
    H.C. Wainwright
    Dyadic International Inc.
    $DYAI
    9/8/2025Buy
    Craig Hallum
    MetaVia Inc.
    $MTVA
    9/4/2025$12.00Buy
    H.C. Wainwright
    Beyond Air Inc.
    $XAIR
    7/17/2025$11.00Buy
    D. Boral Capital
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    MetaVia Inc.
    $MTVA
    12/30/2024$12.00Buy
    H.C. Wainwright
    Beyond Air Inc.
    $XAIR
    6/25/2024Buy → Neutral
    BTIG Research
    More analyst ratings

    $AEMD
    $CVKD
    $DYAI
    $ICU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

    Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of treatment, with durable pain reduction and significant improvements in all key secondary endpoints as compared to placebo In pooled post hoc analysis of the pivotal RELIEF and RELISIENT studies, TONMYA showed favorable benefit-risk profile using number needed to treat, number needed to harm, and likelihood to be helped or harmed BERKELEY HEIGHTS, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, com

    3/10/26 8:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

    The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com KING OF PRUSSIA, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. Mr. Bitterman

    3/10/26 7:59:39 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Morris Jessica Edgar

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    2/26/26 7:03:32 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Saenger Bradley

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    2/26/26 7:03:05 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Sullivan Gregory M

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    2/26/26 7:02:37 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Dyadic International with a new price target

    H.C. Wainwright resumed coverage of Dyadic International with a rating of Buy and set a new price target of $3.00

    10/23/25 7:06:50 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Dyadic International

    Craig Hallum initiated coverage of Dyadic International with a rating of Buy

    9/8/25 8:52:07 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on MetaVia with a new price target

    H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    9/4/25 9:02:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    SEC Filings

    View All

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    3/10/26 8:05:34 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/9/26 9:05:16 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Dyadic International Inc.

    8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    3/6/26 5:04:30 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Leadership Updates

    Live Leadership Updates

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET. This will be a live, interactive online event where investors are invited to ask the company questions

    3/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Financials

    Live finance-specific insights

    View All

    Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

    TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m. ET to present and discuss the topline analysis from the Phase 2 repeated dose clinical study of NS002, the Company's intranasal powder epinephrine product candidate. A question-and-answer session will follow the data presentation. Conference call & webcast info: Monday, March 16, 2026, at 08:00 a.m. ETIndividuals may register for the webcast at

    3/9/26 8:30:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:42:22 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:40:17 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care